NovaGenesis Peptide Research
← Peptide Library
SIGNALLING RESEARCHCJC

CJC-1295 + Ipamorelin

A combined research blend of CJC-1295 (a GHRH analog) and Ipamorelin (a selective GHRP), studied for synergistic growth-hormone axis signalling and pulsatile release patterns.

Half-Life
Moderate–Long
Onset
Gradual
Symbol
CJC
Category
Signalling

⏱ Half-Life

Moderate–Long duration profile

CJC-1295 + Ipamorelin demonstrates a moderate–long half-life characteristic in research literature, shaping how observation windows and study timelines are typically structured.

⚡ Onset Characteristics

Gradual measurable response

Onset is observed as gradual — a property that influences how researchers structure comparative studies versus other compounds in the signalling research category.

🧠 Key Notes

What makes it distinct

  • 01Combines a GHRH analog with a selective GHRP for additive signalling
  • 02Ipamorelin is studied for its selective profile vs other GHRPs
  • 03Frequently referenced in long-duration endocrine research

🧬 Mechanism of Action

How it works

CJC-1295 (without DAC) is a stabilised analog of growth-hormone-releasing hormone (GHRH) that binds the pituitary GHRH receptor to amplify natural GH pulses. Ipamorelin is a selective ghrelin/GH-secretagogue receptor (GHS-R) agonist that triggers GH release through a complementary pathway. Used together, they act on two separate receptors in the somatotroph cells, producing a synergistic GH pulse that is larger than either compound alone but still preserves the body's natural pulsatile rhythm. Critically, Ipamorelin is highly selective — it does not meaningfully stimulate cortisol or prolactin release, isolating the GH-axis effect.

✨ Documented Benefits

What the research shows it supports

B01Stimulates a stronger, more physiological GH pulse than either compound alone.
B02Preserves natural pulsatile GH rhythm — unlike CJC-1295 with DAC, which produces flat GH elevation.
B03Supports lean mass, recovery, and connective-tissue research outcomes.
B04Improves sleep depth and slow-wave sleep architecture in published studies.
B05Minimal cortisol or prolactin elevation — cleaner endocrine profile than older GHRPs (GHRP-2, GHRP-6).
B06Supports IGF-1 elevation and downstream anabolic and repair signalling.

🔍 Research Insights

What the literature shows

INSIGHT 01

The two molecules act on complementary receptors — GHRH and ghrelin — producing a synergistic, more physiologic GH pulse than either alone.

INSIGHT 02

Ipamorelin's selectivity means minimal cortisol or prolactin elevation in research, isolating GH-axis effects.

INSIGHT 03

CJC-1295 (without DAC) preserves the body's natural pulsatile release pattern, unlike its longer-acting DAC counterpart.

🧪 Typical Research Use Cases

Where it appears in study design

USE CASE 01

Pulsatile growth-hormone axis research.

USE CASE 02

Recovery and lean-mass composition modelling.

USE CASE 03

Comparative endocrine studies vs Tesamorelin.

📚 References

Peer-reviewed literature

Primary research sources cited on this profile. All links resolve to PubMed or the publishing journal.

  1. [01]

    Teichman, S. L. et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.

    J Clin Endocrinol Metab ↗
  2. [02]

    Raun, K. et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.

    European Journal of Endocrinology ↗
  3. [03]

    Sinha, D. K. et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology, 9(Suppl 2), S149–S159.

    Translational Andrology and Urology ↗
  4. [04]

    Alba, M. et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology — Endocrinology and Metabolism, 291(6), E1290–E1294.

    Am J Physiol Endocrinol Metab ↗

Continue Exploring

Also explore: MOTS-c, TB-500, Retatrutide

MOTS-c →TB-500 →Retatrutide →Half-Life Guide →Signalling Research →